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Regulatory T (Treg) cells are the major arbiter of immune responses, mediating actions through the
suppression of inflammatory and destructive immune reactions. Inappropriate Treg cell frequency or
functionality potentiates the pathogenesis of myriad diseases with ranging magnitudes of severity. Lack
of suppressive capability hinders restraint on immune responses involved in autoimmunity and
alloreactivity, while excessive suppressive capacity effectively blocks processes necessary for tumor
destruction. Although the etiology of dysfunctional Treg cell populations is under debate, the
ramifications, and their mechanisms, are increasingly brought to light in the medical community.
Methods that compensate for aberrant immune regulationmay not address the underlying complications;
however, they hold promise for the alleviation of debilitating immune system-related disorders. The
dominant immunoregulatory nature of Treg cells, coupled with recent mechanistic knowledge of natural
immunomodulatory compounds, highlights the importance of Treg cells to practitioners and researchers
of complementary and alternative medicine (CAM).
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Behind the Line of Defense: Treg Cell Relations
to Self and Allogeneic Bodies
The intricacies of immune system constituents and interrela-
tionships have been recognized, along with a descriptive
appraisal of regulatory T (Treg) cell function in relation
to allergy and infection (1,2). The objective of this article is
(i) to explain Treg cell function in cancer, autoimmunity and
alloresponses and (ii) to examine the pathological costs of
irregular Treg cell activity. Due to the high frequency and
established knowledge of cancer, autoimmunity and allogeneic
immunity, these three afflictions will be utilized as models
to communicate the significance and relevance of Treg cells to
complementary and alternative medicine (CAM).
Enhanced cell- and humoral-mediated inflammatory
responses, resulting from autoimmune and allogeneic diseases,
destroy tissues, while depressed immune responses to tumor
tissue allow for tumor immunity. Recent evidence has served
to elucidate the mechanism of action and substantiate the
usage of a wide array of traditional herbs, folk medicines,
plant-derived polyphenols and other compounds found in
nature, that are employed to attenuate complications related to
aberrant functioning of immune responses in these diseases
(3–9). Of interest to practitioners, researchers and patients
of CAM modalities are those compounds that maintain
powerful immunoregulatory capacity via direct or indirect
action on Treg cells (see Table 1).
Cancer manifestation and severity depends on a number of
factors including the location and character of the malignancy
as well as occurrence of metastasis. It is mainly a disease of the
later years and one of the leading causes of death in developed
nations. Traditional therapies for cancer including surgery,
chemotherapy and radiotherapy are losing popularity due to
gradual development of tumor resistance to therapy and
non-specific toxicity toward normal cells (19). New thera-
peutic options and possibilities with higher specificity,
efficacy and safety are desirable.
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known as ‘kalmegh’, which grows abundantly in India and
is cultivated in China and Thailand. The phytochemical
extracts from the leaves and stems include diterpenes,
flavonoids and stigmasterols, granting it a variety of pharma-
cological activities and potential for usage in traditional
systems (16). Andrographolide, a biologically active constitu-
ent of A. paniculata, is a potential anticancer agent, mediating
these effects through the inhibition of cancer cell prolifera-
tion and the destruction of cancer cells (16). The proposed
mechanisms by which Andrographolide exerts its anticancer
effects include direct cell cycle arrest and indirect stimulation
of immune system cells. Immunostimulatory activity of andro-
grapholide is evidenced by increased IL-2 and TNF-a
production and enhancement of lymphocyte proliferation,
resulting in strengthened response and cytotoxic activity of
lymphocytes against cancer cells (15,16). The pharmacolo-
gical activity suggests that andrographolide is good candidate
for development as a therapeutic agent or a lead compound in
anticancer and immunomodulatory therapeutics (16).
Therapeutics designated for immune suppression in autoim-
munityandalloresponsesinGraft-versus-Host-Disease(GvHD)
and Host-versus-Graft-Disease (HvGD) include total body
irradiation, chemotherapy and immunosuppression, via corti-
costeroids. Each of these treatments is weighted down with a
variety of deleteriousside effects, primarily increased incidence
and severity of infection and abnormal tissue growth (2,20).
Triptolide (TPT) is a biologically active compound that
is isolated from the Chinese medicinal plant, Tripterygium
wilfordii Hook F. (10,11). TPT demonstrates potent anti-
inflammatory and immunosuppressive actions inhibiting
autoimmunity, allograft rejection and GvHD (11). These
effects were previously attributed to the suppression of
T cells; however, recent studies of its functions on dendritic
cells (DCs), in T cell-mediated immunity, has been explored.
Usage of TPT in a model for skin graft rejection in mice,
demonstrated that TPT impairs allostimulatory functions,
i.e. inhibition of maturation and trafficking of DCs, resulted
in the prevention of graft rejection (10). Chemoattraction of
neutrophils and T cells by DCs may favor their interactions
and the initiation of immune response; therefore, the attenu-
ation of DC frequency and activity by TPT significantly
impairs chemoattraction of effector T cells (11).
Treg cells have been demonstrated to suppress antigen-
specific T cell responses against tumors and allografts, and
implicated in the control of autoimmune diseases (21–24).
CAM benefits from the research done to establish a
scientific basis for various CAM treatment modalities, as it
lends credibility and, most importantly, offers efficacious
treatment options to a large segment of the population afflicted
with cancer, autoimmune disease and alloreactive responses.
Knowledge of the dynamic relationship between Treg cells and
immune system responses to self and allogeneic antigens is
essential in order to approach Treg cells as a clinical target for
the alleviation of severe complications arising from immune
system dysregulation.
Too Much of aGood Thing:ExcessiveTreg Cell
Suppression in Tumor Immunity
Cancer is a category of diseases characterized by the
uncontrolled division of cells and the ability of these cells to
Table 1. Biologically active CAM products with immunomodulatory capacity
Natural product Plant source Medicinal system Utility Mechanism Reference
Triptolide Tripterygium
wilfordii Hook F.
Chinese Immunosuppression
in graft acceptance
Inhibition of NF-kB activation (10,11)
Inhibit maturation and
trafficking of DCs and
effector cells
Berbamine Berberis julianae,
Berberis poiretii
Chinese Immunosuppression
in graft acceptance
Decrease ratio of CD4
þ
to CD8
þ cells
(12)
Piperine Piper longum Linn. Asian and the
Pacific Island
Immunostimulation in cancer,
especially melanoma
Increase white blood cell count (13,14)
Increase bone marrow cellularity
and a-esterase cell population
Increase circulating antibodies
and antibody cells
Inhibit NF-kB
Andrographolide Andrographis paniculata Indian Ayurveda Immunostimulation in cancer Increase lymphocyte proliferation (15,16)
Increase production of IL-2
and TNF-a
Herbkines Eight species of
Oriental herbs
Oriental Medicine Immunostimulation in cancer. Enhance TH1 and TH2 cytokine
production of IFN-g, TNF-a,
IL-2, IL-4 and IL-12
(17)
Sairei-to Twelve species of
medical herbs
Japanese Kampo Immunosuppression in
autoimmune diseases,
especially rheumatoid arthritis
systemic lupus ethythematosus
Decrease TH1 cell-mediated
inflammation
(18)
Enhance TH2 cell functionality
Decrease IgG1 levels
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Excessive and uncontrollable cell division is due to mutations
in the gene’s encoding for protein regulators of cell cycle and
mitosis, e.g. proto-oncogenes and tumor suppressor genes
(TSG), such that signals for cell growth overwhelm regulatory
signals. Mutations may be passed down through genetic
inheritance or can be caused by carcinogens, radioactive
materials and viral genome insertions. The rate of mutations
increases with age, leading to an accumulating reservoir of
damaged DNA sufficient to transform a normal cell into a
malignant one.
Activation of the aryl hydrocarbon receptor (AhR) on Treg
cells induces proliferation and subsequent Treg cell-mediated
immune suppression. Carcinogenic hydrocarbons found in
cigarette smoke, broiled meats and elsewhere in the environ-
ment have the capacity to act as potent activating ligands for
AhR. The induction of profound immune suppression via AhR
activation can result in tumor development (25,26). Although,
these compounds are of great toxicological concern, they offer
researchers the ability to elucidate Treg cell manipulation
through AhRs.
T cells are essential for the destruction of cancer cells;
therefore, inefficient immune responses to cancer cells allow
for their preservation (27). Many tumor-associated antigens
are normal self-constituents; therefore, they are presumably
under the control of Treg cells (28). Since Treg cells are
involved in the suppression of TH1 cell-mediated immune
system function, it follows that Treg cells protect tumors from
attack. Elevated levels of tumor-specific Treg cells have been
found in tumor sites as well as tumor-infiltrating lymphocyte
populations, in lung, breast and ovarian tumors and implicated
in Hodgkin’s lymphoma (27,29). The mechanism for sequest-
ration of Treg cells to tumor tissue, which yields the increased
suppression of immune system attack, is apparently due to
chemokine ligand 22 (CCL22). CCL22 is secreted by tumor
cells and attracts Treg cells from their normal residence, in the
lymph nodes, to the tumor tissue area (30–34). The result is
significant suppression of CD8
þ cells, allowing for tumor
immunity and progression (35). Measuring the ratio of Treg
cells to total T cells present, in tumor tissue, showed that the
higher the ratio, the farther the cancer had progressed and the
more dire the prognosis (28). Interestingly, TGF-b secreted
by most melanomas could play a critical role, as it is one of
the suppressive mechanisms of Treg cells (29). Also naive Th0
cells may develop into Treg cells when exposed to TGF-b (29).
Misidentification of Self as Foe: Dysfunctional
Immunoregulation in Autoimmune Responses
Autoimmune disease occurs when there is a breech in the
normal processes producing tolerance to self, i.e. the failure to
respond to specific autoantigens (28). Antigen presenting cells
(APC), either DCs or macrophages, process specific autoanti-
gens that migrate to the draining lymph nodes. In the lymph
node region, APCs can present these autoantigens to autore-
active T cells, which have escaped negative selection by the
thymus and have evaded peripheral tolerance. This activation
of autoreactive T cells leads to their clonal expansion and
migration to the specific tissues, where they induce inflam-
mation and tissue destruction (36).
Central tolerance and peripheral tolerance comprise the two
mechanisms by which the immune system hinders the
autoreactive T cells from inducing their deleterious functions.
Central tolerance is mediated through negative selection. This
process entails the elimination, through clonal deletion of
autoreactive T cells, during ontogenic development in the
thymus (28).
Peripheral tolerance is the backup available if central
tolerance fails and autoreactive cells escape the thymus. This
mechanism of tolerance occurs continuously throughout life,
keeping autoreactive cells in check through immune ignor-
ance, peripheral deletion and active suppression. Treg cells
maintain peripheral tolerance and regulate autoimmunity
(28,37). Thymically derived Treg cells (nTreg) are the main
regulatory cells involved, utilizing an array of TCRs targeted
towards autoantigen recognition in order to maintain immune
homeostasis in the periphery, and regulate autoimmunity and
pathogenic immune responses (22–24). The pathological
response of autoreactive effector cells can be suppressed by
actions of nTreg cells and the peripherally induced Tr1 and
TH3 cells, each using different mechanisms (28,38,39).
Treg cells mediate the prevention of autoimmunity in two
ways. The first involves the prevention of autoreactive T cell
priming and differentiation in the draining lymph nodes.
Located around DCs in the lymph nodes, Treg cells can prevent
the early stages of T cell activation (40). If this early stage of
T cell activation is not suppressed, autoreactive T cells migrate
to target tissue inducing inflammation and tissue destruction
(36,41). The second of Treg cell suppression involves the
activation, proliferation and trafficking of Treg cells to
the affected tissue to suppress effector cell functions locally.
Treg cell activity is confined to the microenvironment where
they are activated, due to their antigen-specific nature (23).
Figure 1. Decrease in Treg cell frequency and/or function leaves autoimmune
development and progression unregulated. A number of CAM therapeutics
may restore balance through suppression of the autoreactive processes directly
or indirectly through Treg cell manipulation.
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to a number of debilitating autoimmune diseases including,
multiple sclerosis (MS), rheumatoid arthritis (RA), myasthenia
gravis (MG), autoimmune polyglandular syndrome type II
(APS-II),Hashimoto’s thyroiditis(HT),type-1diabetes(T1D),
systemic lupus erythematosus (SLE) and autoimmune lymph-
oproliferative syndrome (ALS) (37,38,42–46) (Fig. 1).
Multiple Sclerosis
Multiple sclerosis is a chronic inflammatory disease charac-
terized by lymphocyte infiltration and inflammation of the
central nervous system white matter. Effector T cells specific
for myelin protein peptides are involved. Decreased numbers
and dysfunction, e.g. low cloning potential in the presence
of IL-2, in Treg cells may allow for the over stimulation of
CD4
þ effector cells upon antigenic challenge, resulting in
the production of proinflammatory cytokines and neuronal
damage (24,37,42,47).
Experimental autoimmune encephalomyelitis (EAE) is a
TH1 cell-mediated inflammatory disease of the central nervous
system, and provides a model of human MS from which
exploration of Treg cell functionality in autoimmune detriment
is possible. Activation of Treg cells with cognate antigen,
proteolipid protein-1 (PLP1), carried on a proteolipid protein
produced an antigen-specific Treg cell capable of suppressing
PLP1 peptide induced EAE in a mouse model (48–50). Thus,
there is the suggestion that the induction and activation
of peptide-specific Treg cells, by a cognate autoantigen, is
essential for the broad immune suppressive functions integral
to the attenuation of autoimmunity. Demonstration of the
potency of Treg cells, expanded with a single epitope, against
autoimmunity is encouraging for CAM researchers to apply
this knowledge to patients with MS and other autoimmune
diseases.
Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory disorder
leading to the destruction of joint architecture. The pathogenic
events leading to the development of RA is not well
understood; however, the presence of proinflammatory
cytokines plays a key role in the development and maintenance
of RA. RA patients’ nTreg cells are able to suppress effector
T cell proliferation, yet incapable of suppressing TNF-a and
IFN-g production. Suggesting that dysfunction of nTreg cells
ability to suppress cytokine production contributes to etiology
of RA (42).However, in a number of cases peripheral Treg cells
suppress the proliferation of effector T cells, but do not
effectively limit proinflammatory cytokine secretion, e.g. anti-
TNF-a or anti-IL-17 therapy suppresses inflammation in
afflicted patients (43,51).
An increased frequency of Treg cells in directly related to
reduced severity of RA. Thus, Treg cell proliferation and
activity in the periphery and joints is essential for prevention
of rheumatic disease and their dysfunction is implicated in
pathogenesis (43).
Autoimmune Myasthenia Gravis
Autoimmune myasthenia gravis is a well characterized auto-
immune disease affecting neuromuscular transmission. MG
is CD4
þ T cell dependent, mediated by anti-acetylcholine
receptor (anti-AChR) autoantibodies. MG patients show no
difference in frequency and proliferation from normal
controls, but exhibit a markedly attenuated ability to suppress
effector T cell proliferation. Therefore, the pathogenesis
and progression of MG may be dependent upon aberrant
Treg cell functioning due to abnormally low levels of FoXP3
production, and subsequent decrease in Treg cell regulatory
capacity (43).
Autoimmune Polyglandular Syndrome Type II
Autoimmune polyglandular syndrome type II is a multiple
endocrine disease initiated by an autoimmune process. The
hallmarks of APS-II include the occurrence of two or more
of the following diseases: Addison’s disease, T1D or auto-
immune thyroid disease. No difference is seen in frequency,
surface markers, death rates or FoXP3 expression of Treg cells
in APS-II patients; however, there is a significant decrease
in suppressor function, resulting in failure to suppress pro-
liferation of effector T cells (42).
Autoimmune Thyroiditis
Hashimoto thyroiditis (HT) is an organ-specific autoimmune
disease characterized by lymphocyte infiltration of the thyroid
that leads to follicular destruction. Thyroglobulin (Tg)-specific
T cells are generated and migrate to the thyroid where they
produce IFN-g, facilitating apoptosis of thyrocytes through
caspase activation. The magnitude of the attack on the thyroid
increases by means of further expansion and accumulation
of activated Tg-specific T cells (52). IL-10 produced by
Treg cells, induced by DCs, is essential for suppression of
Tg-specific T cell responses, targeted lymphocyte infiltration
and follicular destruction (53,54).
Type-1 Diabetes
Type-1 diabetes (T1D) is a chronic TH1 cell-mediated
autoimmune disease that destroys the insulin-producing b
cells in the islets of Langerhans within the pancreas, in
genetically prone individuals (36,42). A decrease in several
immunoregulatory lineages, including natural killer T cells
and Treg cells is found in T1D, leaving little suppression of the
effector antigen-specific CD4
þ and CD8
þ T cells involved in
the pathogenesis of T1D (36). The deficit of Treg cells is
observed in both newly diagnosed individuals and those with
long-term conditions. Functional capacity of Treg cells is also
needed (42).
Two methodologies have proven effective in the pursuit of
utilizing Treg cells to prevent or reverse T1D. Boosting the
regulation of T cells via healthy Treg cells has been accom-
plished through the activation of Treg cells that respond to the
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a non-T1D mouse into a diabetes-prone mouse (55,56).
Systemic Lupus Erythematosus and Autoimmune
Lymphoproliferative Syndrome
Systemic lupus erythematosus (SLE) and autoimmune lymph-
oproliferative syndrome are chronic, systemic, autoimmune
diseases demonstrated to involve a decreased frequency of
nTreg cells. SLE patients also display B cell hyperreactivity,
defects in lymphoid activation processes, aberrant cytokine
production and a lower percent of Treg cells in population of
peripheral blood mononuclear cells (PBMCs). It is unclear
whether Treg cell function is involved in SLE or ALS etiology
and pathogenesis (42).
Psoriasis
Psoriasis is an inflammatory skin disease which has many
characteristics of a TH1 cell-mediated autoimmune disease.
Activation of autoreactive T cells, and their cytokine secre-
tions, trigger keratinocytes to proliferate and produce psoriasis
(57–61). Dysfunctional Treg cells, with decreased capacity for
CD4
þ suppression, may be the culprit for the unrestrained
T cell proliferation observed (62–65). These findings represent
a critical component of organ-specific autoimmune disease
and their implications for possible therapeutic manipulation of
Treg cells (see Fig. 1).
The role of Treg cells in the active suppression of psoriasis,
seen in Fig. 2, may be applied to other autoimmune diseases
discussed previously. The great potentiality of adoptive
antigen-specific Treg cell transfer impels the research of
CAM modalities and remedies to facilitate such processes
with efficiency and safety.
Rejecting Valuable Donations: Insufficient
Treg Cell Suppression of Allogeneic Reactions
Bone marrow (BM) transplants are utilized to correct myriad
afflictions ranging from primary immunodeficiencies to
hematologic malignancies. In order for a BMT to be successful
it must overcome two alloreactive obstacles: GvHD and graft
rejection, also known as HvGD.
GvHD is common to allogeneic BM transplantations. It
involves the immunologic attack on the cells and tissues of the
recipient by the T cell contaminants contained in the donor
BM. GvHD primarily affects the skin, liver and gastrointest-
inal tract through T cell infiltration of epithelia of these areas.
T cells present in the graft recognize the host tissues as
antigenically foreign and begin an offensive proinflammatory
reaction utilizing TNF-a and IL-1, the conditioning of T cell
activation with cytokine production, adhesion molecule
expression and maturation and trafficking of effector T cells
to the area (66). A variety of host antigens presented to
donor T cell major histocompatibility complexes (MHC), in
particular human lymphocyte antigens (HLAs), are respons-
ible for the initiation of GvHD. Donor T cells are undesirable
as effector cells; however, they are beneficial for graft
acceptance by preventing the recipients immune system from
rejecting the graft. The dual quality of donor T cells implores
research in order to maximize graft acceptance through
downplaying GvHD aspects of donor T cells.
Graft rejection is mediated by the host immune system in
response to the foreign graft cells (20). Dominant transplanta-
tion tolerance to BM and tissue grafts has been induced
in mice. The presence or addition of Treg cells can induce
antigen-specific tolerance to BM grafts, while reduction of
Treg cells may accelerate GvHD and graft rejection. The pro-
posed mechanisms of Treg cell functionality in graftacceptance
Figure 2. The importance of regulatory T cells in controlling lymphoproliferative response of CD4
þ effector cells, expression of IL-2 receptor and level of
cytokine production in healthy subjects and patients with psoriasis. These criss-cross experiments were set for testing psoriatic Treg cells in their ability to inhibit
normal T cell response, and vice versa.
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sion of donor T cell expansion (66). Co-injection of donor
BM and Treg cells, stimulated with donor-type APC and high
levels of IL-2 ex vivo, into mice, resulted in long-term
alloantigen-specific protection of the BM graft (20).
In a similar fashion, Treg cells promote conditions conducive
to long-term acceptance of allografts (67). Activation of
Treg cells could result in the acceptance of donor organs as seen
in Fig. 3. Culturing of Treg cells with IL-2 and antigen from
a donor mouse produced antigen-specific Treg cells. These
cells were infused into skin graft recipient mice, preventing
skin graft rejection even though the mice were also infused
with NK and T cells (68,69). Graft recipient mice, without
introduction of antigen-specific Treg cells, rejected the skin
graft. The observed induction of specific tolerance occurred
with just one injection of antigen-specific Treg cells. This
shows the possibility the generation of antigen-specific
Treg cells, followed by their infusion into a patient, prior to
organ transplantation, may encourage success of organ or
tissue transplants (70).
The aforementioned problems necessitate the discovery of
new methods for immune tolerance, in order to maintain the
life saving benefits of BM grafts without the potential
complications (20).
Mechanisms of Self Preservation: Integral
Functions of Treg Cells for Maintenance of
Immune Harmony
Innovative research of Treg cell involvement in various
pathologies related to autoimmune and alloimmune responses
elucidates the mechanisms involved in disease pathogenesis
and, subsequently, identifies plausible means for ameliorative
therapies. It is apparent that the Treg cell quantity and
activation state are integral and equally important factors
in the development and progression of autoimmunity, allo-
immunity and cancer (71). Increased research is necessary in
order to determine Treg cell functioning in relation to
individual disease states. This will afford CAM researchers
insight into the appropriate means of approaching a variety of
human disorders with respect to Treg cells.
Treg cell’s essential role in the management of immune
response to specific auto, allo and tumor antigens has been
detailed. Harmony between regulatory and effector arms of the
immune system is a necessity for good health (1,2). Treg cell
intricacy and specificity to individual antigens impels further
researchand highlights Treg cell’s overall importance to human
health and CAM. The conceptual framework laid down
provides a solid basis from which to explore the diversity of
therapeutic methodologies possible for the direct manipulation
of Treg cells to attenuate hypersensitivity, cancer, infection,
autoimmunity and alloimmunity.
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